



# Scottish Perinatal Network Guidelines Development Standard Operating Procedure



<b>Title</b>	SPN Guidelines Development Standard Operating Procedure (SOP)				
<b>Version number</b>	1.0				
<b>Date published</b>	26 June 2023				
<b>Status</b>	Active				
<b>Author</b>	SPN Programme Team				
<b>Approvals</b>	NMN Guideline Governance Group	NNN Guideline Oversight Group	NMN CSG	NNN CSG	SPN OSB
<b>Approval Dates</b>	12/06/2023	05/05/2023	17/03/2023	17/03/2023	21/06/2023
<b>Review date</b>	June 2026				



## Contents

1. Guideline Development Process Overview
2. Topic Selection Process
3. Guideline Development Process
4. Ratification and Governance
5. Guideline Publication and Dissemination
6. Review Process
7. Enquiries
8. Appendix 1: Key Contacts
9. Appendix 2: Guideline Template
10. Appendix 3: Medico-Legal Considerations

In the context of this Standard Operating Procedure (SOP), the term “guideline” is predominantly understood as referring to clinical guidance agreed as best practice expert consensus within the maternity, neonatal and perinatal clinical community in Scotland.

While this guideline development process is expected to be informed by relevant and up to date empirical evidence, the process described in this SOP is not designed to be able to produce guidelines that are fully compliant with all aspects of clinical guideline development described in the AGREE II tool. Full compliance with AGREE II is not achievable within Scottish Perinatal Network (SPN) resources.

If a guideline development requires full AGREE II compliance, this must be raised with other relevant guideline producers for inclusion in their own development schedule. Most likely in an NHS Scotland context, this would be SIGN. Topics for new SIGN guidelines can be proposed here: [www.sign.ac.uk/get-involved/propose-a-topic](http://www.sign.ac.uk/get-involved/propose-a-topic) . There is more information about the development process at: [www.sign.ac.uk/what-we-do/methodology/sign-50-a-guideline-developers-handbook](http://www.sign.ac.uk/what-we-do/methodology/sign-50-a-guideline-developers-handbook).


The SPN guideline SOP includes five key components, summarised in the process overview below:



## Process Overview




# 1: Topic Selection Process






## 2: Guideline Development Process






### 3: Ratification and Governance of SPN Guidelines






## 4: Publication and Dissemination Process








# 5: Guideline Review Process



**!**  
Old versions and retired guidelines must be archived by the SPN programme team for possible future reference



## 6: Enquiries



**!**  
Enquiries about SPN adopted documents originally developed elsewhere will be routed to the chair of the original development group for advice on the response.



## Appendix 1: Key Contacts

As described in step 2.5, each draft guideline will need to be consulted upon widely including:

- the target audience and subject matter experts relevant to the topic, including those outside of maternity or neonatal services
- relevant service users and/or their representatives
- all relevant Scottish Boards / services

There will naturally be a degree of variation to reflect the specific nature of each guideline. As a minimum the consultation should address the undernoted groups:

### Maternity Services:

1. Guideline Development Group
2. NMN Guideline Governance Group
3. NMN Core Steering Group
4. Obstetric Clinical Directors (ask to cascade on to local obstetric colleagues)
5. Heads of Midwifery (ask to cascade on to local midwifery colleagues)
6. Royal College of Midwives Scotland
7. Scottish Group of the Royal College of Obstetricians and Gynaecologists

### Neonatal Services:

1. Guideline Development Group
2. NNN Guideline Oversight Group
3. NNN Core Steering Group
4. Neonatal Consultant Forum
5. Scottish Neonatal Nurses Group
6. Neonatal AHP Forum
7. Scottish Neonatal and Paediatric Pharmacists Group

### Others:

1. Relevant patient groups / third sector partners, e.g. MVPs or Bliss
2. Other relevant clinical specialties or sub-specialties
3. Relevant MCNs, e.g. PMHNS, SCANS, SOCN, SPRUN, SPEG etc

As described in step 4.2, each final guideline needs to be communicated widely prior to publication.

It is anticipated that the key contacts for this communication will in most cases be the same as the key contacts for the consultation listed in this appendix.



## Appendix 2: Guideline Template

Each guideline development group will need to consider how best to ensure the guideline they are developing is well structured and appropriately reflects the unique requirements of its subject matter so that it is fit for purpose as clinical guidance, enabling the reader to get the necessary information quickly, especially in acute or time sensitive situations.

Guideline development groups may wish to consider :

- a. Including flow charts
- b. Including short / quick-read versions
- c. Avoiding lengthy paragraphs
- d. Moving explanatory / educational background information into appendices where possible.

It is anticipated that all SPN guidance will include the following sections as a minimum standard.

1. **TITLE**
2. **DOCUMENT CONTROL**
3. **TABLE OF CONTENT**  
*(hyperlinked to allow readers to move directly to relevant chapters)*
4. **BACKGROUND AND SCOPE**  
*(incl. definitions, risk factors, complications)*
5. **RECOMMENDATIONS AND SUPPORTING EVIDENCE**  
*(giving succinct, clear and action-focused recommendations; indicating the weight of the recommendation and the grade of evidence it is based on)*
6. **MEASUREMENT / IMPLEMENTATION**  
*(consider how the guideline would be implemented in practice and how benefit of the guideline can be demonstrated)*
7. **USEFUL LINKS AND SUPPORT**  
*(e.g. patient information leaflets, signposting to relevant national guidance, websites)*
8. **GUIDELINE DEVELOPERS AND CONFLICTS OF INTEREST**
9. **REFERENCES**



## Appendix 3: Medico-Legal Considerations

All guidelines should carry a disclaimer informing readers of the medico-legal status of the guideline:

This guideline is not intended to be construed or to serve as a standard of care. Standards of care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge and technology advance and patterns of care evolve. Adherence to guideline recommendations will not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care aimed at the same results. The ultimate judgement must be made by the appropriate healthcare professional(s) responsible for clinical decisions regarding a particular clinical procedure or treatment plan. This judgement should only be arrived at following discussion of the options with the patient, covering the diagnostic and treatment choices available. It is advised, however, that significant departures from the national guideline or any local guidelines derived from it should be fully documented in the patient's case notes at the time the relevant decision is taken.

(Adapted from *SIGN 50: A guideline developer's handbook*, section 1.4 (page 7): [sign50\\_2019.pdf](#))

The Chief Medical Officer has previously issued advice on the medico-legal considerations around the application of clinical guidelines:

“It is distinct from standards which generally reflect a minimum expectation. One of the core principles of Realistic Medicine is that Evidence Based Medicine is comprised of three separate components – not solely the scientific evidence, but taken together with clinical judgement and elicitation of patient preferences. Were legal proceedings arising, it would seem reasonable for a person raising a case about the actions of a Health Board to ask whether the Board had had reasonable regard to this guidance in the way they had acted. But there would be nothing novel in that: it would be a normal course of action to assess whether a public authority had had regard to extant guidance.”